Lesions of Uncertain Malignant Potential (B3)

(ADH, LIN, FEA, Papilloma, Radial Scar)
Lesions of Uncertain Malignant Potential (B3) (including “Precursor Lesions”)

- **Versions 2005–2017:**
  Albert / Audretsch / Brunnert / Fersis / Friedrich / Friederichs / Gerber / Kreipe / Nitz / Rody / Schreer / Sinn / Thomssen / Huober / Kreipe

- **Version 2018:**
  Friedrich / Sinn
B-Classification*

B1 = unsatisfactory or normal tissue only
B2 = benign lesion
B3 = lesion of uncertain malignant potential
B4 = suspicion of malignancy
B5 = malignant
   B5a = non-invasive
   B5b = invasive
   B5c = in situ/invasion not assessable
   B5d = non epithelial, metastatic

* National Coordinating Group for Breast Screening Pathology (NHSBSP),
E.C. Working Group on Breast Screening Pathology, S3-Leitlinie Mammakarzinom der DKG
B3-Lesions

1. **Lesions with increased risk of associated DCIS or invasive carcinoma**
   - Atypical ductal hyperplasia (ADH) or atypical epithelial proliferation of ductal type (classification possibly as B4, depending on extent of lesion)
   - Flat epithelial atypia (FEA)
   - Lobular neoplasia, classic type (LN; ALH and LCIS)
   - Atypical apocrine adenosis

2. **Potentially heterogeneous lesions with risk of incomplete sampling**
   - Cellular fibroepithelial lesion or phyllodes tumour without evidence of malignancy
   - Intraductal papilloma with/without atypia (possibly also B4, depending on the extent of the lesion)
   - Radial scar or complex sclerosing lesion (unless the radial scar only microscopically, not radiologically detected: B2)
   - Hemangioma

3. **Rare Lesions**
   - Adenomyoepithelioma, microglandular adenosis, mucocele-like lesion, nodular fasciitis, desmoid-type fibromatosis, spindle cell lesion of unknown significance
Main types of B3-Lesions and Prospective Predictive Value (PPV) of Malignancy in Resection Specimen (DCIS/inv. Ca.)

<table>
<thead>
<tr>
<th>B3-Lesions:</th>
<th>~PPV</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Atypical ductal hyperplasia (ADH)</td>
<td>20–30 %</td>
</tr>
<tr>
<td>- Lobular intraepithelial neoplasia (LN/LIN)</td>
<td>0–10 %</td>
</tr>
<tr>
<td>- Flat epithelial atypia (FEA)</td>
<td>0–10 %</td>
</tr>
<tr>
<td>- Radial scar / Complex sclerosing lesion</td>
<td>0–10 %</td>
</tr>
<tr>
<td>- Papilloma without atypia</td>
<td>0–10 %</td>
</tr>
<tr>
<td>- Cellular fibroepithelial tumors / phyllodes tumors</td>
<td>0%</td>
</tr>
</tbody>
</table>
Management after Minimally Invasive Biopsy

- Interdisciplinary conference: Concordant findings in pathology and imaging?
  - yes: proceed according to histologic type
  - no: open biopsy

Vacuum-assisted biopsy (after core biopsy)

<table>
<thead>
<tr>
<th>Oxford</th>
<th>LoE</th>
<th>GR</th>
<th>AGO</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>3a</td>
<td>C</td>
<td>++</td>
</tr>
<tr>
<td></td>
<td>3a</td>
<td>C</td>
<td>++</td>
</tr>
<tr>
<td></td>
<td>5</td>
<td>D</td>
<td>+</td>
</tr>
</tbody>
</table>
Atypical ductal Hyperplasia (ADH)

- **Synonyms:** Atypical intraductal epithelial proliferation (AIDEP), atypical epithelial proliferation of ductal type

- **Definition:** Atypical intraductal proliferations with cytological and structural features of well differentiated DCIS, such as rigid bridging or micropapillae, well demarcated cell borders and occupy less than two separate duct spaces. The extension of all involved lumens within one ductulo-lobular unit is less than 2 mm. Atypical ductal proliferations larger than 2 mm or in at least two ductules are classified as DCIS (low-grade).

- **Indicator/Precursor lesion:** Ipsi- and contralateral breast cancer risk: RR 3 - 5 x after 3 - 5 years.

- Classification in DIN 1 - 3 (ductal intraepithelial neoplasia grade 1 - 3) is not sufficiently validated.
Strategy after Diagnosis of ADH in Biopsy Specimen

ADH in core- / vacuum-assisted biopsy:

→ Open excisional biopsy

→ Open excisional biopsy may be omitted, with:
  a) No mass-lesion radiologically, and
  b) a small lesion (≤ 2 TDLU*) in vacuum biopsy, and
  c) complete removal of imaging abnormality

ADH at margins in open biopsy specimen:

→ No further surgery, if incidental finding accompanies invasive or intraductal carcinoma

* Terminal ductal-lobular unit
## Risk of Breast Cancer after Atypical Hyperplasia (ADH, ALH)

### Stratification of breast cancer risk*

<table>
<thead>
<tr>
<th>Category</th>
<th>Number of Foci</th>
<th>RR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of Foci</td>
<td>1</td>
<td>2.65 (2.06-3.41)</td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>5.19 (3.59-7.52)</td>
</tr>
<tr>
<td></td>
<td>≥ 3</td>
<td>8.94 (5.48-14.59)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Category</th>
<th>Present</th>
<th>RR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Microcalcifications</td>
<td>Present</td>
<td>3.21</td>
</tr>
<tr>
<td></td>
<td>Not present</td>
<td>4.21</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Category</th>
<th>Present</th>
<th>RR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Type</td>
<td>Ductal</td>
<td>3.83</td>
</tr>
<tr>
<td></td>
<td>Lobular</td>
<td>3.67</td>
</tr>
<tr>
<td></td>
<td>Both</td>
<td>7.10</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Category</th>
<th>Age</th>
<th>RR</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>&lt; 45</td>
<td>6.76</td>
</tr>
<tr>
<td></td>
<td>45–55</td>
<td>5.10</td>
</tr>
<tr>
<td></td>
<td>&gt; 55</td>
<td>2.67</td>
</tr>
</tbody>
</table>
Lobular Intraepithelial Neoplasia (LIN)

- **Includes**: Atypical lobular hyperplasia, lobular carcinoma in situ, LCIS/CLIS
- LIN 1 - 3 classification is not sufficiently validated prognostically
- Pleomorphic LIN and LIN with comedo-type necrosis are classified as premalignant → **B5a**
- **Indicator/Precursor lesion:** Ipsilateral and contralaterally increased breast cancer risk: 7 x after 10 years
Classical LIN and Variants of LIN with increased risk

Classical LIN

LIN with comedo type necrosis

Florid LIN

Pleomorphic LIN
Pleomorphic LCIS: high grade cellular atypia, frequent involvement of ductules, comedo-type necrosis, microcalcifications

Florid LCIS: Involvement of numerous lobuli with distension and near confluence, extension to ductules and neighbouring TDLU

Type of LCIS with 21 cases of LCIS with microinvasion*:
- classical LCIS: n=11
- florid LCIS: n=4
- pleomorphic LCIS: n=1

Strategy after Diagnosis of LIN

- **LIN in core-/vacuum-assisted biopsy:**
  - No further studies when LIN (classical variant) represents an incidental or isolated finding in core or vacuum biopsy and concordance in imaging
  - Open excisional biopsy, with pleomorphic LIN, florid LIN, or LIN with comedo type necrosis or when not concordant with imaging findings

- **LIN at margins of resection specimen (BCT):**
  - No further surgery

- **Exceptions:**
  a) Pleomorphic LIN, florid LIN, or LIN with necrosis
  b) Imaging abnormality is not removed
  - Complete resection

Oxford

<table>
<thead>
<tr>
<th>LoE</th>
<th>GR</th>
<th>AGO</th>
</tr>
</thead>
<tbody>
<tr>
<td>2b</td>
<td>C</td>
<td>++</td>
</tr>
<tr>
<td>2b</td>
<td>C</td>
<td>++</td>
</tr>
<tr>
<td>2a</td>
<td>C</td>
<td>++</td>
</tr>
</tbody>
</table>

5 D ++
Flat Epithelial Atypia (FEA)

- **Synonyms:** Columnar cell hyperplasia with atypia, columnar cell metaplasia with atypia, ductal intraepithelial neoplasia grade 1A (DIN 1A)

- **Differential diagnosis:**
  - ADH is discriminated by architectural features (micropapillary, cribriform) → B3
  - Clinging carcinoma is discriminated by high grade nuclear atypia (G2/G3) and classified as ductal carcinoma in situ → B5a

- **Marker lesion:**
  FEA frequently is associated with calcifications and may be associated with low-grade intraductal carcinoma. Therefore, histologic step sectioning and correlation with imaging are mandatory.
## Strategy after Diagnosis of FEA

### FEA in core biopsy/vacuum-assisted biopsy:

- Open excisional biopsy may be omitted under the following circumstances:
  - a) a small lesion (≤ 2 TDLU* in vacuum biopsy) and
  - b) Complete or near complete removal of imaging abnormality

- Representative open excisional biopsy in radiologically extensive microcalcifications or discordance to the radiological result

<table>
<thead>
<tr>
<th>Oxford LoE</th>
<th>GR</th>
<th>AGO</th>
</tr>
</thead>
<tbody>
<tr>
<td>3b</td>
<td>C</td>
<td>+</td>
</tr>
<tr>
<td>5</td>
<td>C</td>
<td>+</td>
</tr>
</tbody>
</table>

### FEA at margins in resection specimen:

- No further surgery, unless calcifications have not been completely removed

<table>
<thead>
<tr>
<th>Oxford LoE</th>
<th>GR</th>
<th>AGO</th>
</tr>
</thead>
<tbody>
<tr>
<td>3b</td>
<td>C</td>
<td>++</td>
</tr>
</tbody>
</table>

* Terminal ductal-lobular unit
Papilloma

- **Includes:** Central and peripheral papilloma > 2 mm, atypical intraductal papilloma (B3)
- To be **distinguished from** peripheral micropapilloma arising in the TDLU, size ≤ 2 mm, may be multiple
- To be distinguished from papilloma with DCIS, from intraductal papillary carcinoma, and from encapsulated papillary carcinoma
- **Indicator lesion:**
  May be associated with in-situ or invasive cancer (in case of atypical papilloma up to 20%), increased ipsilateral risk for cancer (4.6% to 13% in case of atypical papilloma)
Strategy after Diagnosis of Central Papilloma

- **Papilloma without atypia in core needle or vacuum biopsy:**
  - no further therapy, when biopsy sufficiently representative (100 mm$^2$) and no discordance to imaging
  - Oxford: 3a, C, ++

- **Multiple papillomas**
  - open biopsy
  - Oxford: 3a, C, ++

- **Papilloma with atypia in core needle or vacuum biopsies:**
  - open biopsy
  - Oxford: 3a, C, ++

- **Papilloma at resection margin:**
  - no published data available
  - Oxford: 3a, C, ++
Radially Sclerosing Lesion

- Benign pseudoinfiltrative lesion with central fibroelastic core and radical configuration.
- Includes:
  - radial scar
  - complex sclerosing lesion (> 1 cm)
- Additional risk factor in patients with benign epithelial hyperplasia (proliferating breast disease)
- Risk for upgrade in open biopsy after diagnosis of radial-sclerosing lesion in core biopsy: 8.3% (79/948)*

Strategy after Diagnosis of Radial Scar, Complex Sclerosing Lesion (CSL)

- **Radial scar / CSL in core-/ vacuum-assisted biopsy:**
  - Open excisional biopsy may be omitted with a small (< 5mm) lesion or complete removal or near complete removal of imaging abnormality

- **Radial scar / CSL at margins in resection specimen:**
  - No further surgery
Follow-up Imaging for Women Age 50-69 Years with B3-Lesions

**FEA, non-atypical papilloma**
- Screening mammography

**LIN**
- Mammography (12 months)

**ADH**
- Mammography (12 months)
- Women with LIN and ADH should be informed about their elevated risk of breast cancer

<table>
<thead>
<tr>
<th>Oxford</th>
<th>LoE</th>
<th>GR</th>
<th>AGO</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>5</td>
<td>C</td>
<td>++</td>
</tr>
<tr>
<td></td>
<td>3a</td>
<td>C</td>
<td>++</td>
</tr>
<tr>
<td></td>
<td>3a</td>
<td>C</td>
<td>++</td>
</tr>
</tbody>
</table>
Medical Prevention for Lesions with Uncertain Biological Behavior (incl. LIN, ADH)

- **Tamoxifen for women >35 years** – Risk reduction of invasive BrCa and DCIS
  - Oxford: 1a, A, +

- **Aromatase inhibitors (Exemestan, Anastrozole)** for postmenopausal women
  - Oxford: 1b, A, +/-

- **Raloxifen for postmenopausal women** - Risk reduction of invasive BrCa only
  - Oxford: 1b, A, +/-*

Medical prevention should only be offered after individual and comprehensive counseling; the overall benefit is dependent on classification, age and pre-existing conditions that may influence the occurrence of side effects.

* Risk situation as defined in NSABP P1-trial (1.66% in 5 years)
**Prevention for Lesions with Uncertain Biological Behavior (Tamoxifen)**

**NSABP-P2 Study, STAR trial 2006**

<table>
<thead>
<tr>
<th></th>
<th>Placebo Rate / 1000 WE</th>
<th>Tamoxifen Rate / 1000 WE</th>
<th>RR</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>All women</td>
<td>6.29</td>
<td>3.59</td>
<td>0.57</td>
<td>0.46-0.70</td>
</tr>
<tr>
<td>± LCIS</td>
<td>5.93</td>
<td>3.41</td>
<td>0.58</td>
<td>0.46-0.72</td>
</tr>
<tr>
<td>+ LIN</td>
<td>11.70</td>
<td>6.27</td>
<td>0.54</td>
<td>0.27-1.02</td>
</tr>
<tr>
<td>w/o ADH</td>
<td>5.87</td>
<td>3.69</td>
<td>0.63</td>
<td>0.50-0.78</td>
</tr>
<tr>
<td>+ ADH</td>
<td>10.42</td>
<td>2.55</td>
<td>0.25</td>
<td>0.10-0.52</td>
</tr>
<tr>
<td>5-year-risk &lt;2%</td>
<td>4.77</td>
<td>3.18</td>
<td>0.67</td>
<td>0.43-1.01</td>
</tr>
<tr>
<td>5-year-risk &gt; 5%</td>
<td>11.98</td>
<td>5.15</td>
<td>0.43</td>
<td>0.28-0.64</td>
</tr>
<tr>
<td>Relative 1. grade</td>
<td>6.47</td>
<td>3.48</td>
<td>0.54</td>
<td>0.34-0.83</td>
</tr>
<tr>
<td>&gt; 3 relatives 1. grade</td>
<td>11.24</td>
<td>5.48</td>
<td>0.49</td>
<td>0.16-1.34</td>
</tr>
<tr>
<td>Fractures</td>
<td>2.88</td>
<td>1.97</td>
<td>0.91</td>
<td>0.51-0.92</td>
</tr>
<tr>
<td>Endometrial cancer</td>
<td>0.68</td>
<td>2.24</td>
<td>3.28</td>
<td>1.87-6.03</td>
</tr>
</tbody>
</table>

Should only be offered to women with enhanced breast cancer risk (Gail ≥1.66%):
- LIN, with ADH
- Family history of breast cancer

Should not be offered to women:
- With moderate risk and > 50 year of age
- With enhanced risk for thrombembolism
Prevention for Lesions with Uncertain Biological Behavior (Tamoxifen, Side Effects)

Risks and Benefits with long-term Tamoxifen use compared with placebo: results from the IBIS-I Trial 96 months median follow-up (Cuzick J et al J Natl Cancer Inst 2007:272-282)

<table>
<thead>
<tr>
<th>Incidence</th>
<th>RR</th>
<th>95% CI</th>
<th>AR je 1000*</th>
<th>NNT / NNH**</th>
</tr>
</thead>
<tbody>
<tr>
<td>Breast cancer</td>
<td>0.73</td>
<td>0.58-0.91</td>
<td>15</td>
<td>68</td>
</tr>
<tr>
<td>Invasive carcinoma</td>
<td>0.74</td>
<td>0.58-0.94</td>
<td>12</td>
<td>81</td>
</tr>
<tr>
<td>Thrombembolism</td>
<td>1.72</td>
<td>1.27-2.36</td>
<td>14</td>
<td>73</td>
</tr>
<tr>
<td>Deep vein thrombosis leg</td>
<td>1.84</td>
<td>1.21-2.82</td>
<td>9</td>
<td>115</td>
</tr>
<tr>
<td>Headache</td>
<td>0.93</td>
<td>0.87-0.99</td>
<td>25</td>
<td>39</td>
</tr>
<tr>
<td>Gynecological-/ vasomotoric symptoms</td>
<td>1.08</td>
<td>1.06-1.10</td>
<td>64</td>
<td>16</td>
</tr>
<tr>
<td>Chest pain</td>
<td>0.77</td>
<td>0.70-0.84</td>
<td>58</td>
<td>17</td>
</tr>
</tbody>
</table>

AR*: Absolute risk per 1000 women. NNT/NNH** = number needed to treat or number needed to harm

Data shown are statistically significant associations for a follow-up-period of 96 month.

Calculations by the authors of the guideline. Visvanathan K et al. JCO 2009;27:3235-3258.
Prevention for Lesions with Uncertain Biological Behavior (Raloxifene)

NSABP-P2 Study, STAR Trial 2006

<table>
<thead>
<tr>
<th></th>
<th>Tamoxifen: Rate / 1000 WE</th>
<th>Raloxifen Rate / 1000 WE</th>
<th>RR</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>All women</td>
<td>4.30</td>
<td>4.41</td>
<td>1.02</td>
<td>0.82-1.28</td>
</tr>
<tr>
<td>± LIN</td>
<td>3.76</td>
<td>3.89</td>
<td>1.03</td>
<td>0.81-1.33</td>
</tr>
<tr>
<td>+ LIN</td>
<td>9.83</td>
<td>9.61</td>
<td>0.98</td>
<td>0.58-1.63</td>
</tr>
<tr>
<td>± ADH</td>
<td>4.06</td>
<td>4.03</td>
<td>0.99</td>
<td>0.76-1.28</td>
</tr>
<tr>
<td>+ ADH</td>
<td>5.21</td>
<td>5.81</td>
<td>1.12</td>
<td>0.72-1.74</td>
</tr>
</tbody>
</table>

Should only be offered to women with enhanced breast cancer risk:

- (Gail ≥ 1.66%) or postmenopausal

Should not be offered to women:

- With moderate risk > 50 year of age
- With enhanced risk for thromboembolism
### Prevention for Lesions with Uncertain Biological Behavior (Aromatase Inhibitors)

**Inclusion criteria:**

- **IBIS.2:**
  - Prior ADH, ALH, or LCIS
    - Anastrozole: 154 (8.0%)
    - Placebo: 190 (9.7%)
  - Yes (7J-MaCa-Risiko 12.1\%): HR 0.31 (0.12–0.84)
  - No (7J-MCa-Risiko 4.9\%): HR 0.52 (0.31–0.78)

- **MAP.3:**
  - Prior ADH, ALH, or LCIS:
    - Exemestane: 185 (8.1%)
    - Placebo: 188 (8.3%)
  - Yes: HR=0.61 (0.20–1.82)
  - No: HR=0.26 (0.11–0.64)

---

**Results for prior ALH, ADH, LCIS (HR Al vs Plac):**

- **IBIS.2:**
  - Prior ADH, ALH, or LCIS
    - Anastrozole: 154 (8.0%)
    - Placebo: 190 (9.7%)
  - Yes (7J-MaCa-Risiko 12.1\%): HR 0.31 (0.12–0.84)
  - No (7J-MCa-Risiko 4.9\%): HR 0.52 (0.31–0.78)

- **MAP.3:**
  - Prior ADH, ALH, or LCIS:
    - Exemestane: 185 (8.1%)
    - Placebo: 188 (8.3%)
  - Yes: HR=0.61 (0.20–1.82)
  - No: HR=0.26 (0.11–0.64)

---